Prothena Corporation

Prothena Corporation ROE

The Return on Equity (ROE) of Prothena Corporation (PRTA) as of Oct 10, 2026 is -87.03 %. In the previous year, Return on Equity (ROE) was -25.12 % — a change of 246.47% (lower).

ROE

-87.03 %

YoY

246.47%

Last updated:

In 2025, Prothena Corporation's return on equity (ROE) was -87.03 %, a 246.47% increase from the -25.12 % ROE in the previous year.

The Prothena Corporation ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-48.19 USD
Jan 1, 2019
-28.46 USD
Jan 1, 2020
-60.40 USD
Jan 1, 2021
14.37 USD
Jan 1, 2022
-18.80 USD
Jan 1, 2023
-26.19 USD
Jan 1, 2024
-25.12 USD
Jan 1, 2025
-87.03 USD
The Prothena Corporation ROE history
YEARROEYoY
-87.03 %+246.47%
-25.12 %-4.09%
-26.19 %+39.31%
-18.80 %-230.82%
14.37 %-123.79%
-60.40 %+112.23%
-28.46 %-40.94%
-48.19 %+28.05%
-37.63 %-14.11%
-43.82 %+96.04%
-22.35 %+806.18%
-2.47 %—
Access this data via the Eulerpool API
Get Free API Key

Prothena Corporation Stock analysis

What does Prothena Corporation do? Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation is one of the most popular companies on Eulerpool.

ROE Details

Decoding Prothena Corporation's Return on Equity (ROE)

Prothena Corporation's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Prothena Corporation's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Prothena Corporation's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Prothena Corporation’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Prothena Corporation stock

Return on Equity (ROE) of Prothena Corporation is -87.03 % in 2025.

Return on Equity (ROE) of Prothena Corporation changed from -25.12 % to -87.03 %, representing a 246.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Prothena Corporation since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Prothena Corporation with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Prothena Corporation

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Prothena Corporation